This is a repository copy of *Next generation sequencing (NGS) to improve the diagnosis and management of patients with disorders of sex development (DSD).*.

White Rose Research Online URL for this paper:
http://eprints.whiterose.ac.uk/142190/

Version: Accepted Version

1   **Next Generation Sequencing (NGS) to improve the diagnosis and management**

2   **of patients with Disorders of Sex Development (DSD).**

3   Hughes, L.A[1]., McKay-Bounford, K[1]., Webb, E.A[2]., Dasani P[1]., Clokie, S[1]., Chandran, H, McCarthy,

4   L[2]., Mohamed,Z[2]., Kirk, J.M.W[2]., Krone, N.P[2]., Allen, S[1]., Cole, T.R.P[1].

5   [1] West Midlands Regional Genetics Service, Birmingham Women's and Children's NHS Foundation Trust, Birmingham, B15

6   2TG, United Kingdom

7   [2] Department of Endocrinology & Diabetes, Birmingham Women's and Children's Hospital, Steelhouse Lane, Birmingham, B4

8   6NH, United Kingdom

9   Corresponding author and to whom requests for reprints should be addressed:

10   Dr Trevor Cole, Clinical Genetics Unit, West Midlands Regional Genetics Service, Birmingham

11   Women's and Children's NHS Foundation Trust and Birmingham Health Partners, Mindelsohn Way,

12   Birmingham, B15 2TG

13   Phone: 0121 335 8024   Fax: 0121 627 2618   Email: trevor.cole1@.nhs.net

14

16

19

22

23   **Abstract**

24   Disorders of sex development (DSDs) are a diverse group of conditions where the chromosomal,

25   gonadal or anatomical sex can be atypical. The highly heterogeneous nature of this group of

26   conditions often makes determining a genetic diagnosis challenging. Prior to Next Generation

27   Sequencing (NGS) technologies, genetic diagnostic tests were only available for a few of the many

28   DSD associated genes, which consequently had to be tested sequentially. Genetic testing is key in

29   establishing the diagnosis, allowing for personalised management of these patients. Pinpointing the

30   molecular cause of a patient's DSD can significantly impact patient management by informing future

1

31   development needs, altering management strategies and identifying correct inheritance pattern when

32   counselling family members.

33   We have developed a 30 gene NGS panel, designed to be used as a frontline test for all suspected

34   cases of DSD (both 46,XX and 46,XY cases). We have confirmed a diagnosis in 25 of the 80 patients

35   tested to date. Confirmed diagnoses were linked to mutations in *AMH, AMHR2, AR, HSD17B3,*

36   *HSD3B2, MAMLD1, NR5A1, SRD5A2 & WT1* which have resulted in changes to patient

37   management. The minimum diagnostic yield for patients with 46,XY DSD is 25/73. In 34/80 patients

38   only benign or likely benign variants were identified, and in 21/80 patients only variants of uncertain

39   significance, (VOUS) were identified, resulting in a diagnosis not being confirmed in these individuals.

40   Our data supports previous studies, that an NGS panel approach is a clinically useful and cost

41   effective frontline test for patients with DSDs.

42

43   **Introduction**

44   Disorders of sex development (DSD) encompass a wide range of conditions with diverse clinical

45   features, pathophysiology and clinical management[1–3]. The recently revised stratified DSD diagnostic

46   pathway consists of clinical examination, biochemical investigations and karyotype determination[4,5].

47   Once a presumptive diagnosis has been made, targeted sequencing of candidate genes may then be

48   performed at a later stage[5]. Whilst reaching the correct diagnosis impacts significantly on

49   management decisions, determining the aetiology of genital ambiguity in patients with DSD on the

50   basis of clinical and biochemical assessment remains challenging[6]. In DSD where no clear

51   abnormality in the steroidogenesis pathway is present, the yield from genetic testing had historically

52   remained low, and with single-gene sequencing was both costly and time consuming[4].

53   Improvements in gene sequencing technology in conjunction with rapidly falling costs have led to the

54   use of targeted next-generation sequencing (NGS) assays. These enable multiple known disease

55   causative genes to be sequenced in parallel alongside initial clinical assessment and biochemical

56   investigations, potentially avoiding the need for additional expensive biochemical and radiological

57   investigations[7]. Reaching a timely diagnosis is extremely important as it ends diagnostic uncertainty,

58   avoids further unnecessary investigations, enables appropriate disease-specific counseling (including

59   assessment of future fertility potential and malignancy risk) and implementation of personalised

60   medical plans in accordance with current disease specific consensus guidelines[8]. Additionally, in the

61   long-term accurate early diagnosis will support the development of better designed outcome studies.

62   The use of targeted next generation sequencing panels for molecular diagnosis of DSD patients has

63   already been reported successfully in several previous publications[9–12]. These publications show

64   diagnostic yield and clinical utility in predominantly 46,XY DSD cohorts using panels of 64-219 genes.

65   We present our data showing sequence analysis of a cohort of 80 DSD patients using a 30 gene

66   panel.

Materials & Methods

67

Patients

68

69   Eighty patients with a DSD were referred to the West Midlands Regional Genetics Laboratory

70   (WMRGL) at the Birmingham Women's and Children's NHS Foundation Trust for diagnostic DSD

71   testing between March 2014 and March 2017, comprising of 73 patients with 46,XY DSD and 7 with

72   46,XX DSD. Referrals were from Clinical Genetics, Urology or Endocrinology specialists. Karyotyping

73   and/or microarray results were typically available to confirm the patient's karyotype. Single gene

74   testing may have also been performed in advance of the NGS screen but a pathogenic mutation had

75   not been identified. Where DNA was available, cascade testing was performed on parental or sibling

76   samples to confirm segregation or to confirm a diagnosis in the proband's similarly affected siblings.

77   Data from cascade testing is not included here; all figures therefore represent only probands referred

78   for diagnostic testing who underwent analysis via the NGS panel. Consent was obtained for clinical

79   testing from all patients in this study. Patients undertaking routine clinical testing in this report are not

80   identifiable. This report has been registered with the audit committee at the Birmingham Women's and

81   Children' Hospital NHS Foundation trust (CARMS-30120).

Gene selection

82

83   Thirty genes with a reported clinical association with a DSD were selected following discussion

84   between the WMRGL and clinical specialists in Genetics and Endocrinology (table 1). Genes include

85   those thought to be involved in 46,XY DSD and 46,XX DSD, and are tested as a single panel pipeline

86   covering both of these groups of patients. The *CYP21A2* gene associated with 95% of cases of

87   Congenital Adrenal Hyperplasia (CAH) is not included in this panel. This is because this patient group

88   typically have a clinical diagnosis prior to genetic testing, and also the *CYP21A2* pseudogene makes

89   accurate mapping of short reads to the functional gene very difficult.

90   **Sample preparation**

91   Genomic DNA was typically extracted from peripheral blood samples using Qiasymphony technology

92   (Qiagen) following the manufacturer's instructions. The concentration of all genomic DNA samples

93   were assessed using a Qubit (Life technologies) prior to sequencing.

94   **Next Generation Sequencing (NGS)**

95   Library preparation was initially performed by a customised TruSeq Custom Amplicon (TSCA, Illumina

96   Inc, San Diego, California) 30 gene panel run on the MiSeq (Illumina Inc, San Diego). Exons were

97   targeted with 25 base pairs of padding on either side, resulting in 431 amplicons of 425bp.

98   Enrichment was performed on 250ng of genomic DNA, and sequencing using 250 base paired-end

99   reads. TruSight One (TSO) technology was then used to capture exonic regions of 4,813 genes,

100   sequencing 24 samples on a HiSeq 2500 (Illumina Inc, San Diego, California). The same 30 DSD

101   genes were analysed as a virtual panel using TSO. A depth of coverage of 20x was considered

102   sufficient for either approach, and a technical report was generated indicating the proportion of each

103   gene covered to this level. All patients that were initially run by TSCA but where a diagnosis was not

104   confirmed were subsequently retested using TSO. NGS was performed on probands only and

105   analysis for copy number variation in these genes was not performed.

106   **Bioinformatic analysis**

107   Bioinformatic analysis was performed using an in-house pipeline where sequence reads were

108   mapped to the human genome hg19 reference. Several programmes are incorporated in the pipeline;

109   Trimmomatic (quality trimming of reads), BWA mem (alignment to hg19), Samblaster (duplicate

110   marking), Abra (realigning), Platypus (variant calling), Annovar (variant annotation) PLINK (IBS

111   calculation) and Picard (calculating hybridisation and mapping metrics). Custom python code and

112   bedtools were used to calculate coverage and the Python module pandas to produce patient specific

113   Excel files.

114   **Variant interpretation and reporting**

115   Variants were classified following the Association of Clinical Genetic Science (ACGS,

116   www.acgs.uk.com) best practice guidelines, based on the American College of Medical Genetics and

117   genomics recommendations[13]. This included utilisation of in-house frequency data, population

118   frequency data (dbSNP, 1000 genomes & EXAC), in-silico tools including Polyphen, Align GVGD and

119   splice tools (searched through the alamut interface), the Human Gene Mutation Database (HGMD

120   Professional, Biobase Corporation), and evidence from peer-reviewed literature. The five classes are

121   described in table 2. For suspected compound heterozygous mutations, parental samples were

122   requested to confirm that the mutations were on opposite alleles (in trans). Regions of interest were

123   all exonic regions plus 30bp upstream and 10bp downstream of each exon. Intronic variants outside

124   of these regions were considered as deep intronic variants (DIVs) and no further investigation was

125   undertaken. In some cases, Sanger sequencing was performed to complete gene coverage to a

126   depth of 20x. For example, where a single heterozygous mutation in a likely candidate gene

127   associated with a recessive condition had been identified.

128

129   **Results**

130   The DSD NGS panel provided a molecular diagnosis in 25 out of the 80 patients tested (table 3). A

131   diagnosis was deemed as confirmed where variants of class 4 or class 5 were identified which were

132   consistent with the inheritance pattern for that gene, and where disruption of the gene was in keeping

133   with the patient's phenotype. On 4 occasions a class 3 variant was found in combination with a class

134   5 mutation (patients 2, 11, 15 & 20). Although technically class 3 variants are of uncertain

135   significance, their presence in combination with a class 5 variant in these patients, when considered

136   with the clinical information provided led us to believe that these findings were causally related to the

137   clinical features. The overall diagnostic yield for this panel is therefore currently 25/80 for all samples

138   and 25/73 for 46,XY DSD. This figure represents the likely minimum detection rate of this panel as

139   some samples were received with an initial request for Sanger sequencing of a specific gene, and

140   typically only included for panel testing if negative on Sanger sequencing.

141

142   Class 3 variants (listed in table 4) were typically missense mutations which had not been previously

143   reported, and therefore no clinical information was available. These were included in the clinical report

144   with a statement that a diagnosis had not been confirmed due to the uncertainty around the

145   pathogenicity of such variants. Where only class 1 and/or 2 variants were identified, patient reports

146   stated that no evidence of a pathogenic mutation had been identified. A summary of the findings can

147   be seen in figure 1. Both previously reported and novel pathogenic mutations and variants were

148   identified in *AMH, AMHR2, AR, DHCR7, HSD17B3, HSD3B2, LHCGR, MAMLD1, NR5A1, SRD5A2*

149   *and WT1* (table 5). Diagnosis due to mutations in the *AR* gene (7 patients) were the most commonly

150   observed (table 3) followed by diagnosis due to HSD17B3 (5 patients) and SRD5A2 (4 patients).

151

152   **Discussion**

153   DSDs, estimated to be present in 1.7% of live births[14] are a diagnostic challenge due to variable

154   expressivity and pleiotrophy, clinical overlap of the different DSD, and their significant aetiological

155   heterogeneity. Historically a genetic diagnosis was made in as few as 13% of cases [15]. We present

156   data from 80 patients who underwent routine diagnostic testing for DSD using a 30 gene NGS panel.

157   This diagnostic DSD panel was utilised irrespective of clinical and biochemical features, unless a

158   specific single Sanger sequence request was made based on phenotypic assessment. The diagnostic

159   yield of this DSD panel was shown to be 25/80 for all DSD's, higher for 46,XY DSD (25/73), and

160   would have been higher in this cohort if all cases with a suspected diagnosis, (all subsequently

161   confirmed on Sanger Sequencing) , had not been filtered out prior to implementation of the panel

162   test. Pathogenic (or likely pathogenic) mutations in the *AMH*, *AMHR2*, *AR*, *HSD17B3*, *HSD3B2*,

163   *MAMLD1*, *NR5A1*, *SRD5A2* and *WT1* genes were identified. Our detection rate and findings are

164   similar to previous studies, summarised in Table 6. Dong *et al* demonstrated an increased detection

165   rate of 9/13 in 46,XY DSD patients using a panel of 219 genes[10], however the study included small

166   patient numbers and so may not be representative.

167

168   Separating out analysis of 46,XY DSD from those with 46,XX DSD results in an improved 46,XY yield

169   to 25/73 but highlights the 0/7 diagnostic yield of individuals with a 46,XX DSD. Difficulty in confirming

170   a molecular diagnosis in those with an 46,XX DSD has also been seen in other studies[11,12]. Sample

171   numbers for those with 46,XX DSD are very small in this study and therefore are unlikely to be

172   representative of the true diagnostic capability of the panel for these patients. In addition, other

173   causes of 46,XX DSD such as translocation of SRY to the X chromosome, duplications of *SOX9* or

174   CAH due to CYP21A2 deficiency are not detectable by this method. Patients would typically have had

175   karyotype and/or microarray prior to testing on the panel and would have been tested separately for

176   CYP21A2 deficiency if CAH was suspected. Increased sample numbers and incorporation of more

177   46,XX DSD associated genes as they are identified may allow a more accurate estimate of the

178   panel's usefulness for those with 46,XX DSD. It will also be important to include new 46,XX DSD

179   genes that are likely to be identified in current international exome/genome sequencing projects such

180   as the 100,000 genome project in England.[16]

181

182   Novel mutations and variants in several genes were identified where functional studies were not

183   available. Variants were considered likely to be causative if they were observed in trans (on opposite

184   chromosome alleles) with a known pathogenic mutation, in a disease gene showing autosomal

185   recessive inheritance (4 patients in our cohort). In some cases, segregation studies confirming the bi-

186   allelic nature of the findings also supported a likely pathogenic role. This information has expanded

187   our knowledge of likely diagnostic DSD variants for future investigation of DSD patients. Novel VOUS

188   in the absence of a confirmed diagnosis were also seen. Whilst their significance currently remains

189   uncertain, wider data sharing through publication of studies such as this is crucial to further our

190   understanding of such variants. The large number of VOUS in this cohort is predominantly due to

191   limited clinical information related to some DSD related genes, for example only VOUS were detected

192   in the *CBX2* gene. Clinicians will have to manage any patient confusion or anxiety within the current

193   uncertainty until more data is available. When designing future NGS DSD panels it will remain

194   important to recognise that increasing the number of genes, especially those with limited data, will

195   generate greater numbers of VOUS with increased cost and complexity of analysis. This should be

196   balanced against the potential for gene discovery.

197

198   Segregation studies have been helpful in determination of pathogenicity in several families, as

199   illustrated by patient 23, who had an Androgen Receptor (*AR)* variant initially reported as a VOUS.

200   The patient's older brother, previously shown to have a 47,XXY karyotype and a "milder" phenotype

201   was subsequently shown to have the same *AR* variant. Given his additional X chromosome, without

202   skewed X inactivation a milder phenotype would be expected. This increased our confidence in calling

203   the variant a "likely pathogenic" mutation and highlights the importance of reviewing interpretation of

204   variants when new information becomes available.

205

206   NGS technology has also allowed the identification of mosaic mutations in the *AR* gene, which may

207   have gone undetected by other methods. Identification of an accurate number of reads enhances our

208   knowledge of the level of mosaicism present. It should be noted, however, that the results represent

209   the mutation load in peripheral blood (70% patient 8 and 30% patient 24) and not necessarily other

210   relevant tissues. Of the mutations identified, both had been previously reported in non-mosaic form in

211   the literature[17,18]. Mosaic mutations have however been reported in the *AR* gene[19,20] and taken

212   together with the clinical features, allowed us to conclude that these mutations in mosaic form were

213   likely to be contributing to the phenotype in these patients. Importantly for patient management, *AR*

214   mutations in mosaic form are believed to pose a risk of virilisation in patients due to the presence of

215   wild type androgen receptor[19]. Distinguishing mosaic from non-mosaic forms therefore can have

216   significant consequences for patient management and genetic recurrence risk.

217

218   Identifying the correct genetic diagnosis modifies the patient management and impacts on the

219   accuracy of information and choices available to family members. The former is clearly illustrated in

220   case 21 where mutations in two different DSD related genes were present in the same family;

221   *HSD17B3* and *AR.* The family were requesting gonadectomy pre-adolescence in a 46,XY DSD

222   female, on the basis that her cousins who were 46,XY DSD females, due to a homozygous *HSD17B3*

223   mutations, had virilised and been managed with gonadectomy in another centre. Identification of a

224   previously unidentified mutation in *AR* in this family meant 3 girls with 46,XY changed their

225   subsequent management. In 4 cases the diagnosis in affected siblings has been confirmed (listed in

226   table 3 patients 7, 17, 21 & 23) including cases enabling early prenatal (patient 20) or neonatal

227   (patient 17) diagnosis, and thus implementation of appropriate management from birth. This highlights

228   the importance of identifying the molecular diagnosis not only for the proband but also for the wider

229   family.

230   The panel also identified pathogenic mutations which were thought to be co-incidental and not to be

231   related to the initial clinical presentation in the proband. In patient 18 with Congenital Adrenal

232   Hyperplasia (CAH) due to HSD3B2 deficiency, the patient was also shown to be a carrier for the

233   common splice mutation c.964-1G>C in the *DHCR7* gene which is linked to Smith Lemli Opitz

234   syndrome (SLOS). Whilst such incidental findings can be challenging for patient counselling, the

235   information provided may also be of great significance. This will be especially true when previously

236   undetected autosomal recessive mutations are uncovered in highly consanguineous families, which

237   are common within many DSD cohorts.

238

239   Where a clinician has a strong suspicion of the involvement of a specific gene, Sanger sequencing

240   may be more cost effective, especially where the number of amplicons is relatively small.   For

241   example pathogenic mutations in the *AMH*, *AMHR2*, *AR* and *SRD5A2* gene were identified in this

242   way. When the original clinical diagnosis is incorrect however, the potential cost savings rapidly

243   disappear if sequential Sanger sequencing is required, and therefore any benefit is highly dependent

244   on the clinical expertise and the specificity of the additional non-genetic investigations. There may

245   also be atypical presentations not yet recognised for mutations in some genes, and therefore a wider

246   panel approach has the potential to address this.

247

248   Despite the diagnostic rate of 25/73 for 46,XY DSD, the failure to achieve a diagnosis in 55 patients

249   confirms the need for further development. Of note, the panel cannot currently detect copy number

250   changes (CNVs), and so further development should include detection of CNVs that are below the

251   resolution of the current chromosomal microarray assay. The 30 genes in our panel were selected

252   due to published evidence of their involvement in DSD, but new gene discoveries in studies such as

253   the 100,000 genome project[16] should enhance the diagnostic utility, especially for 46,XX DSD. Eggers

254   et al demonstrated a 118/278 diagnostic rate for 46,XY DSD patients by including 64 DSD genes[11],

255   and Dong et al reported a 6/13 rate by including 219 genes[10], thus diagnostic capability may be

256   improved by increasing the gene number. These benefits may be marginal however as only one likely

257   pathogenic mutation in the Dong series was in the additional 179 genes not included in this 30 gene

258   panel. Comparison of these studies could indicate that a greater impact on the detection rate may be

259   due to patient selection. It will be important, therefore, that further candidate gene inclusion is critically

260   evaluated as the addition of genes without clear clinical utility will likely result in increasing cost and

261   numbers of VOUS without necessarily increasing diagnostic capability. The future of this investigative

262   pathway may well be transformed by implementation of whole exome or whole genome sequencing,

263   but any benefits of diagnostic detection will have to be weighed against increased cost and clinical

264   complexities resulting from VOUS and co-incidental findings. It therefore remains important to

265   optimise such NGS panels for DSD so that a valid comparison can be made in future.

266

267   This data demonstrates clear advantages of an NGS panel approach for highly heterogenous

268   conditions such as DSD. Despite the limitations of the panel including incomplete coverage and

269   inability to detect copy number changes, the results presented here demonstrate that an NGS based

270   panel approach is a useful frontline tool for diagnosing DSDs. In addition to a diagnostic yield of at

271   least 25/80 we have shown examples of cases where the information provided from the panel has

272   identified diagnoses in complex families with the potential for multiple aetiologies, cases where panel

273   findings have significantly impacted management and treatment decisions, and examples of novel

274   variants being identified, thus expanding our current knowledge. As more and more patients are

275   tested, the information provided by such panels will continue to grow and improve our understanding

276   of these complex conditions and hopefully improve the diagnostic capability of such tests. Despite its

277   limitations, the clinical benefit of this approach is clearly demonstrated for DSD patients allowing for

278   timely accurate diagnoses, more informed management strategies and improved counselling for

279   patients and their families.

280

Declaration of Interest

The authors declare that there is no conflict of interest that could be perceived as prejudicing the

impartiality of the research reported

284

Funding

This work did not receive any specific grant from any funding agency in the public, commercial, or not-

for-profit sector.

288

289

References

291   1.   Biason-Lauber, A. Control of sex development. *Best Pr. Res Clin Endocrinol Metab* **24,** 163–
292   186 (2010).

293   2.   Higashi, Y., Yoshioka, H., Yamane, M., Gotoh, O. & Fujii-Kuriyama, Y. Complete nucleotide
294   sequence of two steroid 21-hydroxylase genes tandemly arranged in human chromosome: a
295   pseudogene and a genuine gene. *Proc Natl Acad Sci U S A* **83,** 2841–2845 (1986).

296   3.   Arboleda, V. A., Sandberg, D. E. & Vilain, E. DSDs: genetics, underlying pathologies and
297   psychosexual differentiation. *Nat. Rev. Endocrinol.* **10,** 603–15 (2014).

298   4.   Ahmed, S. F., Achermann, J. C., Arlt, W., Balen, A. H., Conway, G., Edwards, Z. L., Elford, S.,
299   Hughes, I. A., Izatt, L., Krone, N. *et al.* UK guidance on the initial evaluation of an infant or an
300   adolescent with a suspected disorder of sex development. *Clin. Endocrinol. (Oxf).* **75,** 12–26
301   (2011).

302   5.   Lee, P. A., Nordenström, A., Houk, C. P., Ahmed, S. F., Auchus, R., Baratz, A., Baratz Dalke,
303   K., Liao, L.-M., Lin-Su, K., Looijenga, L. H. J. *et al.* Global Disorders of Sex Development
304   Update since 2006: Perceptions, Approach and Care. *Horm. Res. Paediatr.* **85,** 158–80
305   (2016).

306   6.   Lee, Y. S., Kirk, J. M., Stanhope, R. G., Johnston, D. I., Harland, S., Auchus, R. J., Andersson,
307   S. & Hughes, I. A.. Phenotypic variability in 17beta-hydroxysteroid dehydrogenase-3 deficiency
308   and diagnostic pitfalls. *Clin Endocrinol* **67,** 20–28 (2007).

309   7.   Ahmed, S. F., Bashamboo, A., Lucas-Herald, A. & McElreavey, K. Understanding the genetic

310   aetiology in patients with XY DSD. *Br. Med. Bull.* **106,** 67–89 (2013).

311   8.   Lee, P. A., Houk, C. P., Ahmed, S. F., Hughes, I. A. & Endocrinology, I. C. C. on I. organized

312   by the L. W. P. E. S. and the E. S. for P. Consensus statement on management of intersex

313   disorders. International Consensus Conference on Intersex. *Pediatrics* **118,** e488-500 (2006).

314   9.   Baxter, R. M., Arboleda, V. A., Lee, H., Barseghyan, H., Adam, M. P., Fechner, P. Y.,

315   Bargman, R., Keegan, C., Travers, S., Schelley, S. *et al*. Exome sequencing for the diagnosis

316   of 46,XY disorders of sex development. *J. Clin. Endocrinol. Metab.* **100,** E333-44 (2015).

317   10.   Dong, Y., Yi, Y., Yao, H., Yang, Z., Hu, H., Liu, J., Gao, C., Zhang, M., Zhou, L., Asan, Yi, X. &

318   Liang, Z. Targeted next-generation sequencing identification of mutations in patients with

319   disorders of sex development. *BMC Med. Genet.* **17,** 23 (2016).

320   11.   Eggers, S., Sadedin, S., van den Bergen, J. A., Robevska, G., Ohnesorg, T., Hewitt, J.,

321   Lambeth, L., Bouty, A., Knarston, I. M., Tan, T. Y. *et al.* Disorders of sex development: insights

322   from targeted gene sequencing of a large international patient cohort. *Genome Biol.* **17,** 243

323   (2016).

324   12.   Kim, J. H., Kang, E., Heo, S. H., Kim, G.-H., Jang, J.-H., Cho, E.-H., Lee, B. H., Yoo, H.-W. &

325   Choi, J.-H. Diagnostic yield of targeted gene panel sequencing to identify the genetic etiology

326   of disorders of sex development. *Mol. Cell. Endocrinol.* **444,** 19–25 (2017).

327   13.   Richards, S., Aziz, N., Bale, S., Bick, D., Das, S., Gastier-Foster, J., Grody, W. W., Hegde, M.,

328   Lyon, E., Spector, E. *et al.* Standards and guidelines for the interpretation of sequence

329   variants: a joint consensus recommendation of the American College of Medical Genetics and

330   Genomics and the Association for Molecular Pathology. *Genet. Med.* **17,** 405–423 (2015).

331   14.   Blackless, M., Charuvastra, A., Derryck, A., Fausto-Sterling, A., Lauzanne, K. & Lee, E. How

332   sexually dimorphic are we? Review and synthesis. *Am. J. Hum. Biol.* **12,** 151–166 (2000).

333   15.   Arboleda, V. A., Lee, H., Sánchez, F. J., Délot, E. C., Sandberg, D. E., Grody, W. W., Nelson,

334   S. F. & Vilain, E. Targeted massively parallel sequencing provides comprehensive genetic

335   diagnosis for patients with disorders of sex development. *Clin. Genet.* **83,** 35–43 (2013).

336   16.   Siva, N. UK gears up to decode 100,000 genomes from NHS patients. *Lancet* **385,** 103–104

337   (2015).

338   17.   Galani, A., Sofocleous, C., Karahaliou, F., Papathanasiou, A., Kitsiou-Tzeli, S. & Kalpini-

339   Mavrou, A. Sex-reversed phenotype in association with two novel mutations c.2494delA and

340   c.T3004C in the ligand-binding domain of the androgen receptor gene. *Fertil. Steril.* **90,**

341   2008.e1-2008.e4 (2008).

342   18.   Marcelli, M., Tilley, W. D., Wilson, C. M., Wilson, J. D., Griffin, J. E. & McPhaul, M. J. A single

343   nucleotide substitution introduces a premature termination codon into the androgen receptor

344   gene of a patient with receptor-negative androgen resistance. *J. Clin. Invest.* **85,** 1522–8

345   (1990).

346   19.   Holterhus, P. M., Wiebel, J., Sinnecker, G. H., Brüggenwirth, H. T., Sippell, W. G., Brinkmann,

347   A. O., Kruse, K. & Hiort, O. Clinical and molecular spectrum of somatic mosaicism in androgen

348   insensitivity syndrome. *Pediatr. Res.* **46,** 684–90 (1999).

349   20.   Köhler, B., Lumbroso, S., Leger, J., Audran, F., Grau, E. S., Kurtz, F., Pinto, G., Salerno, M.,

350   Semitcheva, T., Czernichow, P. *et al.* Androgen Insensitivity Syndrome: Somatic Mosaicism of

351   the Androgen Receptor in Seven Families and Consequences for Sex Assignment and

352   Genetic Counseling. *J. Clin. Endocrinol. Metab.* **90,** 106–111 (2005).

353

354

355

356   Figure 1: Summary of findings of DSD panel.

357   Results of the panel are separated by karyotype (XX or XY) and by result. 'Diagnosis

358   confirmed' indicates patients where a pathogenic variant was detected compatible with the

359   patient's phenotype. 'VOUS (Variant Of Uncertain Significance) only' indicates solely Class 3

360   variants were detected and therefore a diagnosis could not be confirmed. 'No mutation'

361   indicates only Class 1 (polymorphisms) or Class 2 variants (unlikely to be pathogenic) were

362   detected.

363

184x126mm (96 x 96 DPI)

46,XY DSD	Gene Name	Location
Disorders of testicular development	ARX	Xp22.13
	ATRX	Xq13.3
	CBX2	17q25
	DHH	12q13.1
	DMRT1	9p24.3
	MAMLD1	Xq28
	NR0B1	Xp21.3
	NR5A1	9q33
	SOX9	17q24-q25
	SRY	Yp11.3
	TSPYL1	6q22-23
	WNT4	1p35
	WT1	11p13
Disorders of Hormone synthesis or action	AMH	19p13.3-p13.2
	AMHR2	12q13
	AR	Xq11-q12
	CYB5A	18q23
	CYP11A1	15q23-24
	CYP17A1	10q24.3
	DHCR7	11q12-q13
	HSD3B2	1p13.1
	HSD17B3	9q22
	LHCGR	2p21
	POR	7q11.2
	SRD5A2	2p23
	StAR	8p11.2

46,XX DSD	Gene Name	Location
Disorders of ovarian development	RSPO1	1p34.3
	SOX9	17q24
	SRY	Yp11.3
	WNT4	1p35
Androgen Excess	CYP11B1	8q21-q22
	CYP19A1	15q21
	HSD3B2	1p13
	NR3C1	5q31
	POR	7q11.2

Table 1b

Table 1a

Table 1: Genes included in the DSD panel

A summary of all genes and their chromosomal location which are included in the panel for both 46,XY DSD (table 1a) and 46,XX DSD (table 1b). CAG repeat in *AR* not analysed to avoid incidental diagnosis of Spinal bulbar muscular atrophy.

1

Variant class	Variant description	Confirmation by Sanger	Reported
1	Polymorphism	No	No
2	Unlikely to be pathogenic	No	Yes
3	Variant of uncertain significance (VOUS)	Yes	Yes
4	Likely to be pathogenic	Yes	Yes
5	Clearly pathogenic	Yes	Yes

Table 2: Classification and follow up of variants. All variants determined to be class 3-5 were confirmed using Sanger sequencing and all were included in the clinical reports. Variants considered to be unlikely to be pathogenic (class 2) were not confirmed by Sanger sequencing and were recorded for information only in the clinical report. Class 1 variants were not reported.

1

Patient	Sex	Reason for referral	Gene	Allele 1	Allele 2	Results reported and follow up
1	XY M	?PAIS	AR	c.2402C>T p.(Thr801Ile)		Confirmed diagnosis of PAIS.
2	XY M	?PMDS	AMH	c.283C>T p.(Arg95*)	c.905G>A p.(Arg302Gln)	Consistent with diagnosis of PMDS.
3	XY F	?46,XY DSD	NR5A1	c.1171A>T p.(Lys391*)	Normal	Consistent with a diagnosis of a 46,XY DSD. **Novel mutation**.
4	XYᵖ F	?46,XY DSD	HSD17B3	c.614T>A p.(Val205Glu)	c.645A>T p.(Glu215Asp)	Supports diagnosis of 46,XY DSD due to HSD17B3 deficiency.
5	XYᵖ F	?46,XY DSD	HSD17B3	c.194C>T p.(Ser65Leu)	c.729_735del7 p.(Ile244Argfs*11)	Supports diagnosis of 46,XY DSD due to HSD17B3 deficiency.
6	XYᵖ M	?46,XY DSD	SRD5A2	c.698+1G>T	c.698+1G>T	Consistent with diagnosis of 46,XY due to SRD5A2 deficiency.
7	XYᵖ M	X-linked hypospadias	MAMLD1	c.1366C>T p.(Arg456*)		Consistent with MAMLD1 associated hypospadias. Confirmed in 2 affected brothers and mother (carrier). Carrier of PMDS (c.35T>G p.(Val12Gly) in AMH.
8	XYᵖ M	?46,XY DSD	AR	c.2391G>A p.(Trp797*)		Mosaic (70% of reads). Likely causally related to clinical features.
9	XY F	?XY DSD	NR5A1	c.69 C>A p.(Tyr23*)	Normal	Consistent with diagnosis of 46,XY DSD. **Novel mutation**.
10	XY F	?46,XY DSD	HSD17B3	c.695C>T p.(Ser232Leu)	c.695C>T p.(Ser232Leu)	Confirms diagnosis 46,XY DSD due to HSD17B3 deficiency.
11	XYᵖ M	?PMDS	AMHR2	c.813_817delGCTCT, p.(Leu272Trpfs*24)	c.931G>A, p.(Gly311Ser)	Consistent with features of PMDS. **Novel mutation and novel variant.**
12	XY F	?46,XY DSD	SRD5A2	c.737G>A, p.(Arg246Gln)	c.737G>A, p.(Arg246Gln)	Consistent with diagnosis of SRD5A2 deficiency.
13	XYᵖ M	Penoscrotal hypospadias	SRD5A2	c.586G>A, p.(Gly196Ser)	c.586G>A, p.(Gly196Ser)	Consistent with diagnosis of SRD5A2 deficiency assuming XY.
14	XY M	Gynaecomastia, Hypospadias, micropenis	AR	c.2057T>C p.(Val686Ala)		Consistent with clinical features. Confirmed inherited from mother.
15	XY M	Ambiguous genitalia	HSD17B3	c.277+4A>T	c.133C>T p.(Arg45Trp)	Consistent with clinical features. c.13C>T p.(Arg45Trp) is **novel variant.**
16	XY F	?AIS	AR	c.2343G>A p.(Met 781Ile)		Consistent with diagnosis of AIS.
17	XY M	?PMDS	AMHR2	c.289C>T p.(Arg97*)	c.289C>T p.(Arg97*)	Confirms diagnosis of PMDS. Both parents carriers. Also had another child affected child who was homozygous for the same mutation (detected in neonatal period).
18	XY M	?XY DSD	HSD3B2	c.518T>G p.(Leu173Arg)	c.518T>G p.(Leu173Arg)	Confirms diagnosis of CAH due to HSD3B2 deficiency. Both parents are carriers. Patient also a carrier of the c.964-1G>C splice mutation in DHCR7.
19	XYᵖ F	?46, XY DSD	HSD17B3	c.277+4A>T	c.645A>T p.(Glu215Asp)	Confirmed diagnosis of 46, XY DSD due to 17-Beta Hydroxysteroid dehydrogenase deficiency. Each parent carries 1 mutation.
20	XY M	Undervirilised male	SRD5A2	c.307C>T p.(Arg103*)	c.107A>G, p.(His36Arg)	Consistent with clinical features. Parental samples confirmed compound heterozygous. Follow up biochemical testing confirmed SRD5A2 deficiency. **Novel variant**.
21	XY F	?XY DSD	AR	c.2407dupC p.(Gln803Profs*27)		Confirms diagnosis of AIS. Two affected siblings also have mutation. **Novel mutation.** Also heterozygous for HSD17B3 familial mutation. **c.**803G>A p.(Cys268Tyr).
22	XY M	Ambiguous genitalia	WT1	c.1087A>T p.(Arg363*)	Normal	May be contributing to features. Confirmed de-novo. Tumour screening initiated.
23	XY M	Severe hypospadias	AR	c.2384T>A p.(Phe795Tyr)		Initially reported as VOUS. Once identified in affected (milder) brother who's karyotype was 47,XXY more confident that linked to features. **Novel variant.**
24	XY M	Severe hypospadias and penile transposition	AR	c.2645T>C p.(Leu882Pro)		Mosaic (30% of reads). Likely causally related to phenotype.
25	XY M	?PMDS	AMH	c.649C>T p.(Gln217*)	c.649C>T p.(Gln217*)	Consistent with diagnosis of PMDS. **Novel mutation**.

Table 3: Patient details with a confirmed molecular diagnosis

Details of mutations and variants found in patient reported with a confirmed molecular diagnosis. Details of the karyotypic and phenotypic sex are in the second column with M and F representing phenotypic sex. P indicates presumed karyotype (reports not seen) from SRY sequence reads. Pathogenic mutations linked to the diagnoses listed in "gene column". Allele 1 and 2 describe the mutations in the different alleles, a black box indicates an absent second X allele in XY individuals. Green = Normal (wildtype), Yellow = Class 3 variant (Variant Of Uncertain Significance (VOUS)), Orange = Class 4 variant (Likely pathogenic), Red = Class 5 variant (Clearly pathogenic). AIS = Androgen Insensitivity Syndrome, CAH = Congenital Adrenal Hyperplasia, PAIS = Partial Androgen Insensitivity Syndrome, PMDS = Persistent Mullerian Duct Syndrome.

2

Patient	Sex	Reason for referral	Gene	Allele 1	Allele 2	Results reported and follow up
26	XY ?	N/A	POR	c.948-30G>A	Normal	A molecular diagnosis has not been confirmed
27	XYᵖ M	1º gonadal failure, short stature	WT1	c.11C>G, p.(Pro4Arg)	Normal	A molecular diagnosis has not been confirmed
28	XY M	Mullerian resistant disorder	HSD17B3	c.133C>T p.(Arg45Trp)	Normal	A molecular diagnosis has not been confirmed
29	XY M	?46,XY DSD	RSPO1	c.658C>T p.(Arg220Trp)	Normal	A molecular diagnosis has not been confirmed
30	XY M	Hypogonadism	HSD3B2	c.809T>C p.(Ile270Thr)	Normal	A molecular diagnosis has not been confirmed
31	XY F	Facial dysmorphism, gastric motility issues, undescended testes, adrenal insufficiency	CBX2	c.1411C>G p.(Pro471Ala)	Normal	A molecular diagnosis has not been confirmed. #Variant found in alternative transcript.
			CBX2#	c.616C>T p.(Gln206*)	Normal	
32	XX M	Hypospadias	NR5A1	c.275G>A p.(Arg92Gln)	Normal	A molecular diagnosis has not been confirmed
33	XY F	? Gonadal dysgenesis	CYP11A1	c.1250T>G p.(Val417Gly)	Normal	A molecular diagnosis has not been confirmed
34	XY F	? CYP11A1 imbalance	CYP11A1	c.989C>T p.(Thr330Met)	Normal	A molecular diagnosis has not been confirmed
			MAMLDI	c.2009C>T p.(Thr670Ile)		
35	XY F	Primary ovarian failure	WT1	c.1493A>G p.(Glu498Gly)	Normal	A molecular diagnosis has not been confirmed
36	XY M	Severe penoscrotal hypospadias.	CBX2	c.1416C>G p.(Asp472Glu)	Normal	A molecular diagnosis has not been confirmed
			HSD3B2	c.500C>T p.(Ala167Val)	c.500C>T p.(Ala167Val)	
37	XY F	Tall stature, uterus present, no obvious ovaries	CBX2	c.1411C>G p.Pro471Ala	Normal	A molecular diagnosis has not been confirmed
			AMH	c.53C>T p.(Ala18Val)	Normal	
			AMH	c.1556C>T p.(Ala519Val)	Normal	
38	XX F	Premature ovarian failure	CYP11B1	c.1451T>A p.(Val484Asp)	Normal	A molecular diagnosis has not been confirmed
39	XY F	Clitoromegaly, no vaginal opening	AR	c.1174C>T p.(Pro392Ser)		Pathogenicity of variant uncertain due to conflicting evidence
40	XY M	Penoscrotal hypospadias, micropenis & undescended testes	CBX2	c.785G>A p.(Arg262Gln)	Normal	A molecular diagnosis has not been confirmed
41	XY M	Hypospadias and penoscrotal transposition	CYP11A1	c.940G>A p.(Glu314Lys)	Normal	A molecular diagnosis has not been confirmed
			HSD17B3	c.133C>T p.(Arg45Trp)	c.133C>T p.(Arg45Trp)	
42	XY M	?46,XY DSD	LHCGR	c.828delC p.(Ser277Alafs*32)	Normal	A molecular diagnosis has not been confirmed. Variant likely to be pathogenic but absence of second mutation leads to uncertain significance.
			CBX2	c.785G>A p.(Arg262Gln)	Normal	
43	XY M	Ambiguous genitalia	NR5A1	c.146G>A p.(Cys49Tyr)	Normal	A molecular diagnosis has not been confirmed. De novo variant.
44	XYᵖ F	?46,XY DSD	NR5A1	c.1019C>T p.(Ala340Val)	Normal	A molecular diagnosis has not been confirmed. Maternally inherited.
45	XY M	Ambiguous genitalia	HSD17B3	c.202-22G>A	c.202-22G>A	A molecular diagnosis has not been confirmed. Recommend biochemical testing.
46	XX F	Ambiguous genitalia, complete labial fusion	LHCGR	c.458+3A>G	Normal	A molecular diagnosis has not been confirmed
			NR5A1	c.486C>T p.(=)	Normal	

Table 4a: Patients with Variants of Uncertain Significance (VOUS) where a diagnosis was not confirmed

1

Patient	Sex	Reason for referral	Gene	Allele 1	Allele 2	Results reported and follow up
3	XY F	?46,XY DSD	ATRX	c.2595C>G p.(His865Gln)		ATRX & AMH variants found in in addition to NR5A1 class 4 mutation (table 3).
			AMH	c.-2C>T	Normal	
4	XY F	? 46,XY DSD	MAMLD1	c.2744A>C p.(Asp915Ala)		MAMLD1 variant found in addition to HSD17B3 mutations (table 3)
7	XY M	X-linkedhypospadias	AMH	c.35T>G p.(Val12Gly)	Normal	AMH & CBX2 variants found in addition to MAMLD1 class 4 mutation (table 3)
			AMH	c.-74C>G	Normal	
			CBX2	c.565G>A p.(Ala189Thr)	Normal	
19	XY F	?46,XY DSD	MAMLD1	c.728G>A p.(Cys243Tyr	Normal	MAMLD1 variant found in addition to HSD17B3 mutations (table 3)
22	XY M	Ambiguous genitalia	ATRX	c.546A>G p.(=)	Normal	ATRX variant found in addition to WT1 mutation (table 3)

Table 4b: Patients with variants of Uncertain Significance where a diagnosis has been confirmed.

Table 4: Details of Variants of Uncertain Significance (VOUS) identified.

Details of all VOUS found in this study. Table 4a indicates patients where only VOUS were found i.e. no pathogenic or likely pathogenic variants were identified. As such a diagnosis could not be confirmed in these patients. Table 4b indicates patients where VOUS were found in addition to the pathogenic/likely pathogenic mutations which were believed to be causative of the patients phenotype. Details of the karyotypic and phenotypic sex are in the second column with M and F representing phenotypic sex. P indicates presumed karyotype (reports not seen) from SRY sequence reads. Allele 1 and 2 describe the variants in the different alleles, a black box indicates an absent second X allele in XY individuals. Green = Normal (wildtype), Yellow = Class 3 variant (Variant Of Uncertain Significance (VOUS)), Red = Class 5 variant (Clearly pathogenic).

Table 5: Summary of the frequency of mutations and variants of uncertain significance found for each gene.

The total number of pathogenic mutations (class 4 and 5 variants) and Variants of Uncertain Significance (VOUS, class 3) variants identified in the patients tested. Each mutated allele is given a score of 1 therefore a patient homozygous for a pathogenic mutation (score=2) would be equally represented in the table as a patient who is compound heterozygous for 2 pathogenic mutations.

Gene	Pathogenic (Class 4 or 5)	VOUS Class (3)	Gene	Pathogenic (Class 4 or 5)	VOUS
AMH	3	3	HSD3B2	2	3
AMHR2	3	1	LHCGR	1	1
AR	7	1	MAMLD1	1	1
ARX	0	0	NR0B1	0	0
ATRX	0	0	NR3C1	0	0
CBX2	0	6	NR5A1	2	4
CYB5A	0	0	POR	0	1
CYP11A1	0	3	RSPO1	0	1
CYP11B1	0	1	SOX9	0	0
CYP17A1	0	0	SRD5A2	7	1
CYP19A1	0	0	SRY	0	0
DHCR7	1	0	STAR	0	0
DHH	0	0	TSPYL1	0	0
DMRT1	0	0	WNT4	0	0
HSD17B3	9	6	WT1	1	2

Paper	Number of genes in panel	Number of patients tested and karyotypic sex	Diagnostic Yield Overall	Diagnostic Yield 46,XY	Diagnostic Yield 46,XX
Baxter, 2015 (ref 9)	64	40 XY	-	14/40	-
Dong, 2016 (ref 10)	219	13 XY, 8 XX	8/21*	6/13	2/8
Eggers, 2016 (ref 11)	64	278 XY, 48 XX	126/326	118/278	8/48
Kim, 2017 (ref 12)	67	37 XY, 7 XX	13/44	13/37	0/7
Hughes, 2018	30	73 XY, 7 XX	25/80	25/73	0/7

Table 6: Summary of previous studies using NGS analysis for DSDs

*Dong et al report their detection rate of 46,XY DSD as 9/13 however 3 of these patients had Variants of Uncertain Significance (VOUS) only and therefore using the same parameters as in this study a diagnosis would not be confirmed. Numbers modified above to allow more accurate comparison with this study.